nazariomuibepu1687.blogspot.com
The Rockville-based company’s BioThrax has been granted a shelf life extension from the from its currenty three yearsto four. Under its contract with the Department of Health andHumann Services, the extension triggers a milestone paymentf of $30 million for dosess of the vaccine already delivered to the Strategic National Emergent expects to record that paymenr as revenue this quarter. The shelr life extension also allows Emergent to charg more for future doses of the vaccine deliverefd tothe government’s stockpile.
That coulx raise the value of the contract to as muchas $405 millionb over the next several Last year, the FDA approvede a reduced vaccination schedule to five Emergent continues research that could lead to a further reduction in the numbee of doses required, as well as the vaccine’s use to trea patients after being exposed to not just as a pre-exposure vaccine. Emergent has supplied the government’s stockpile with 33 million doses of BioThraxso far. It is contractexd to continue adding to stockpiles throughlate 2011. BioThrax has been used to vaccinatwe more than 2 million military personneo since the government firs t started buying the vaccinein 1998.
Emergent stoci (NYSE: EBS) was up 90 cents to $14.633 per share in afternoon trading.
Nenhum comentário:
Postar um comentário